EUCTR2011-003799-35-ES进行中（未招募）不适用
RAL-PEP
Fundació Clínic per a la Recerca Biomèdica0 个研究点目标入组 189 人开始时间: 2011年10月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 189
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 18 years or older
- •- HIV exposure requiring prophylaxis under current guidelines
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 189
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 189
排除标准
- •- Pregnancy, nursing, or planned pregnancy during the study period
- •- Suspected drug resistance in source case
- •- Contraindications to the study drugs
研究者
相似试验
招募中
1 期
A Phase 1, Open-Label Study to Investigate the TARP-?8 Receptor Occupancy of RAP-219 Using a TARP-?8 PET Tracer in Healthy Adult ParticipantsMedDRA version: 21.0Level: PTClassification code: 10015037Term: Epilepsy Class: 100000004852EpilepsyCTIS2024-512151-21-00Rapport Therapeutics Inc.24
进行中（未招募）
1 期
/AMedDRA version: 14.0Level: PTClassification code 10066131Term: Congenital central hypoventilation syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000989-35-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
招募中
1 期
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal cancer: a phase I study.CTIS2023-509135-17-00niversitair Ziekenhuis Gent45
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOADCTIS2023-508363-79-00Alnylam Pharmaceuticals Inc.59
尚未招募
1 期
Clinical observation of modified Buzhong Yiqi decoction combined with PKEP in the treatment of BPH with DBenign Prostatic HyperplasiaITMCTR2200006857Fangcun Hospital, Guangdong Provincial Hospital of traditional Chinese Medicine